Citox

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citox

Quick Facts

Property Description
Active ingredient Escitalopram
Form Film-coated tablets, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose To modulate mood and emotional balance
Origin Synthetic compound (S-enantiomer)

What Type of Medicine is Citox and Its Active Ingredient?

Citox is a synthetic, single-ingredient prescription-only medication defined by its active compound, Escitalopram, which belongs to the Selective Serotonin Reuptake Inhibitor (SSRI) class of drugs.

Escitalopram is chemically unique because it is the purified S-enantiomer of the older, racemic Citalopram, a refinement recognized for its focused activity. This chemical distinction ensures greater efficiency and selectivity at the pharmacological target compared to its predecessor. The compound functions as a highly targeted psychotropic agent, differentiating it from broader-spectrum antidepressant classes.


Composition, Forms, and General Therapeutic Purpose

The active component, typically utilized as the Escitalopram oxalate salt, is administered via the oral route in primary dosage forms such as film-coated tablets and, less commonly, an oral solution. The tablets often feature a film coating designed to aid compliance and control dissolution. The overall purpose of this drug is to help stabilize emotional and mood regulation systems in the brain. For instance, the medicine is commonly used to help patients experiencing persistent distress, contributing to a sense of greater emotional equilibrium. By focusing its action on the serotonin system, Citox aims to modulate the neurochemical environment to help restore a functional balance in the central nervous system.

What side effects are possible with Citox?

Possible Side Effects and Safety Information

The medicine's safety profile is documented by regulatory agencies and classifies potential adverse reactions by frequency and the body system affected. This information is based strictly on clinical trial data and post-marketing surveillance.


Adverse Reaction Scope

Category Summary of Regulatory Findings
Frequency classification Very Common (Nausea); Common (Insomnia, Somnolence, Diarrhea, Dry Mouth, Dizziness, Fatigue, Increased Sweating, Sexual Dysfunction including Ejaculation Disorder and Anorgasmia).
Systems involved Psychiatric Disorders, Nervous System Disorders, Gastrointestinal Disorders, Metabolism and Nutrition Disorders, Reproductive System, and Cardiac Disorders.

Serious Adverse Reactions

The official label documents specific, clinically significant risks, including a Boxed Warning concerning Suicidal Thoughts and Behaviors in children, adolescents, and young adults (up to age 24), particularly during the initial months of therapy or following dose adjustments. Other documented serious risks include Serotonin Syndrome, QT-interval Prolongation (a cardiac safety concern), and Hyponatremia (low sodium levels), which is reported to occur predominantly in older adults. The risk of Abnormal Bleeding/Hemorrhage is also documented.

Population and Time-Related Safety

Population-Specific: A reduced dosage is typically recommended for older adults and patients with hepatic impairment. Caution is advised in patients with severe renal impairment. Use in late pregnancy is associated with a risk of Persistent Pulmonary Hypertension of the Newborn (PPHN).

Time-Related Patterns: The risk of suicidal ideation is more prominent during the initial few months of therapy. Sexual dysfunction and weight changes are adverse reactions commonly reported with long-term exposure. Abrupt cessation is associated with discontinuation syndrome symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Citox

The regulatory profile for Citox (Escitalopram) strictly details the clinical manifestations and mandated emergency response actions required in the event of an overdose.

Overdose Scope Documented Regulatory Information
Documented Overdose Presentations: Overdose may present with CNS effects such as dizziness, somnolence, and tremor. Gastrointestinal symptoms like nausea and vomiting are frequently reported, alongside cardiovascular signs, including tachycardia (fast or pounding heartbeat) and hypotension.
Life-Threatening Clinical Outcomes: The most serious outcomes include seizures and coma (loss of consciousness). Fatal cardiac abnormalities, specifically QT prolongation and Ventricular Arrhythmia (Torsade de Pointes), have been reported. Serotonin Syndrome, a potentially life-threatening condition, is also documented.
Emergency Action Triggers: Seek immediate medical attention for any suspected overdose. Call emergency services (911) immediately if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Official Overdose Management Statements:

  • No specific antidote is known for Escitalopram overdose; management is symptomatic and supportive.
  • Close monitoring for cardiac abnormalities and vital signs is required during overdose care.
  • Management for severe symptoms such as seizures often includes the use of Benzodiazepines.

The regulatory profile defines the overdose risk by listing these expected clinical presentations and establishing the critical thresholds—such as collapse or seizure—that necessitate contacting emergency medical services. This structure ensures a defined, officially required response when an overdose situation is suspected, focusing on supportive measures given the absence of a specific counteractive agent.

Therapeutic Uses of Citox

What Citox Treats: Main Uses and Benefits

Citox (Escitalopram) is generally used across several primary mental health domains to provide symptomatic relief and promote emotional stabilization. Its core therapeutic relevance lies in conditions characterized by prominent and persistent distress that interferes with the patient's ability to maintain daily functioning. It may help ease the overall symptom burden when acute or recurrent episodes lead to heightened physiological and emotional tension.

The medicine is commonly used to treat conditions associated with debilitating symptomatic manifestations, including Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, Social Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). Applied in clinical settings that involve acute or unstable symptom patterns, it offers symptomatic relief that helps patients cope more steadily with difficult episodes. This medication is relevant for easing symptoms related to persistent low mood and excessive, uncontrollable worry.

Therapeutic Scope and Benefits

The therapeutic benefit may assist with easing mental apprehension and physical strain, which contributes to improved day-to-day comfort and may assist with maintaining concentration when symptoms intensify. This supportive relief is common in adults, adolescents (MDD), and pediatric patients (GAD).


Quick Fact: Relief for Key Symptom Patterns
Supports patients during difficult episodes by easing distress.
Assists with maintaining functional stability.
Is commonly used across conditions presenting with acute episodes and for supportive long-term management.

Eligibility and Restrictions for Use

Who Can and Cannot Use Citox?

Eligibility for Citox (Escitalopram) is defined strictly by official regulatory labeling, outlining specific populations who are permitted or restricted from use.

Absolute Contraindications

Use of Citox is strictly contraindicated in patients with a known hypersensitivity to escitalopram or citalopram. It must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue. It is also prohibited for patients with a documented history of QT interval prolongation or those taking medicinal products known to prolong the QT interval.

Age and Organ Function Eligibility

Population Group Regulatory Status
Adults (ge 18 years) Approved for standard use.
Adolescents (12 to 17 years) Approved for Major Depressive Disorder (MDD).
Pediatric Patients (7 to 11 years) Approved for Generalized Anxiety Disorder (GAD).
Elderly Patients (ge 65 years) Approved, but requires a recommended lower maximum daily dose.
Hepatic Impairment Requires a recommended lower maximum daily dose.
Severe Renal Impairment Use with caution; data is insufficient for chronic treatment.

Reproductive and Special Population Status

During pregnancy, use is considered appropriate only if the potential benefit justifies the potential risk to the fetus. Caution must be exercised when administering Citox to nursing women. Use requires caution in patients with a history of seizures or mania/hypomania, and use should be avoided in cases of unstable epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Citox interacts with several classes of medicinal products, which requires specific risk management based on official regulatory labeling. These interactions are categorized by the potential for altered drug levels (pharmacokinetic) or additive pharmacological effects (pharmacodynamic).


Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs): Citox must not be used concurrently with MAOIs, including antidepressants (e.g., phenelzine) and other MAOI-acting drugs like linezolid or intravenous methylene blue, due to the risk of serotonin syndrome. A mandatory 14-day washout period is required when switching between Citox and an MAOI.

Pimozide: Co-administration with the antipsychotic Pimozide is contraindicated because Citox can increase Pimozide exposure, significantly raising the risk of QT prolongation.

Clinically Significant Interactions

Serotonergic Drugs: Co-administration with other serotonergic agents (such as triptans, SSRIs, SNRIs, tricyclic antidepressants, and fentanyl) necessitates close monitoring for the signs of serotonin syndrome.

CYP2C19 Inhibitors: Concurrent use of potent inhibitors of the CYP2C19 enzyme (e.g., cimetidine, omeprazole) is documented to increase Citox systemic exposure. For patients taking these medicines, the maximum recommended dosage of Citox is 20 mg/day.

Bleeding Risk: Co-administration with oral anticoagulants (e.g., warfarin), NSAIDs, or Aspirin requires careful monitoring due to the increased risk of abnormal bleeding. St. John’s Wort should also be avoided as it may diminish Citox effects.

Mechanism of Action

Targeted Blockade of Serotonin Clearance

Escitalopram acts as a highly selective inhibitor of the Serotonin Transporter ( SERT) protein. By binding to SERT at the neuronal membrane, the drug prevents the reuptake of Serotonin (5-HT), leading to a rapid and sustained increase in 5-HT levels within the synaptic cleft.


The Time-Dependent Systemic Adaptation

The sustained elevation in 5-HT triggers a time-dependent regulatory process involving the desensitization and downregulation of inhibitory 5- HT1 A autoreceptors. This slow neurobiological adaptation removes an inhibitory brake on 5-HT release, which results in a persistent, elevated Serotonergic signal across the Central Nervous System (CNS).


Modulation of Emotional Regulatory Circuits

This sustained activity modulates feedback loops and promotes neuroplasticity within key areas of the limbic system and prefrontal cortex, which are responsible for processing emotional input. This mechanism ultimately contributes to the adjustment of activity within these crucial CNS circuits.

Dosage and Administration Information

General Principles of Citox Use

Citox (Escitalopram) is administered orally. The medicine is available in various forms, including film-coated tablets in strengths of 5 mg, 10 mg, and 20 mg, and as an oral solution dosed at 1 mg/mL. The medicine is generally taken once daily, either in the morning or evening, and may be administered with or without food.


Dosing and Scheduling

The most common starting dose for adults with Major Depressive Disorder or Generalized Anxiety Disorder is 10 mg once daily. The recommended maximum daily dose for these indications is 20 mg. For conditions such as Panic Disorder, treatment may begin with a lower dose of 5 mg for the first week before increasing to 10 mg. Dose adjustments, or titration, from 10 mg to 20 mg typically follow a minimum interval of one week between changes.


Use Patterns and Administration Constraints

Specific dose considerations apply to certain patient groups. For older adults (over 65 years), the maximum dose is often limited to 10 mg daily. A similar maximum of 10 mg is utilized for patients with hepatic impairment. The scored tablets, such as the 10 mg and 20 mg strengths, are designed to be divisible to facilitate precise dose management.

Regarding the overall treatment plan, the period of use often extends to at least six months following the resolution of symptoms for maintenance. When treatment is planned for cessation, a gradual dose reduction (tapering) is utilized to minimize potential discontinuation effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citox (Escitalopram)


Evidence for Use in Major Depressive Disorder (MDD)

Research has primarily explored the use of Citox in studies of conditions characterized by functional limitations, particularly Major Depressive Disorder (MDD). The core evidence is derived from multiple placebo-controlled Randomized Controlled Trials (RCTs), a common type of study used in regulatory submissions. These studies were used in research exploring how symptoms change over time. Outcomes were measured using specific scales like the MADRS and HAM-D to quantify levels of change in symptom severity. Findings describe patterns observed in the studies over short-term (acute) treatment periods, typically 6 to 8 weeks.

The overall evidence landscape consists of a large volume of data derived from these RCTs and subsequent systematic reviews. Research describes these patterns across various adult populations, as well as in adolescents aged 12 to 17. Findings help contextualize how patients reported their experience. Long-term studies monitored patients for up to 24 weeks or longer to examine symptom recurrence.


Evidence for Use in Generalized Anxiety Disorder (GAD)

Research for Generalized Anxiety Disorder (GAD) also relies heavily on placebo-controlled Randomized Controlled Trials. These studies explored short-term symptom changes, with studies focusing on episodes where symptoms become more noticeable. Researchers monitored outcomes primarily using the Hamilton Anxiety Rating Scale (HAMA) to assess symptom intensity. The studies were applied in research contexts involving fluctuating or unstable symptoms in adults and certain pediatric patients from 7 years old and older.

Acute-phase trials reported how symptoms evolved in the observed populations over periods typically around 8 weeks. For continued outcomes, long-term studies monitored patients for up to 24 weeks or more to examine sustained symptom status. However, research exploring short-term symptom changes has yielded data that are still emerging for the youngest pediatric age groups (under 7 years old).


What is Still Uncertain About the Research Base

The evidence highlights what is known — and what is still uncertain. Long-term effects are not fully established, as continued research is ongoing to monitor the observed outcomes beyond the typical trial period (e.g., beyond one year). Data for certain groups remain insufficient, especially concerning the very young and certain subsets of older adults, meaning results apply only to the specific populations that were studied. Comparative evidence is lacking for direct, head-to-head trials against all other comparable treatments currently available for these conditions.

Frequently Asked Questions (FAQ)

Common questions about Citox (FAQ)


Q: How many weeks does it typically take before Citox starts to show an effect?

A: Clinical studies suggest that initial improvements in certain symptoms like sleep, energy, and appetite may begin to be observed within the first one to two weeks. However, official information indicates that full relief from emotional symptoms often requires six to eight weeks of continued use to become fully noticeable.


Q: How long do the initial, temporary side effects of Citox typically last?

A: According to official product information, many initial, mild adverse effects, such as nausea or headache, are often temporary. These effects may improve or disappear within the first few days or a couple of weeks as the body adjusts to the medicine.


Q: Can Citox affect my ability to drive or operate machinery?

A: Official warnings indicate that caution is necessary when performing activities like driving or operating hazardous machinery. This is because the medicine may cause effects like dizziness or drowsiness that could potentially interfere with cognitive and motor performance.


Q: Is it generally safe to consume caffeine or moderate alcohol while taking Citox?

A: Official labeling notes that alcohol consumption may increase nervous system side effects such as dizziness and drowsiness. For this reason, official information recommends avoiding or limiting the use of alcohol. There is no specific regulatory warning against the general use of caffeine.


Q: How long does Citox or its active components stay in your system after the last use?

A: Studies in regulatory documents indicate the medicine has a mean terminal half-life of approximately 27 to 32 hours. This figure means it takes roughly one to one-and-a-half days for half of the drug to be eliminated from the body.


Q: Is Citox a generic drug or only available under a brand name?

A: The active component, Escitalopram, is the generic name for the medicine. According to official drug status information, the medicine is available under its generic name as well as various brand names.


Q: Is Citox considered a scheduled or controlled substance in certain regions?

A: In the United States, this medicine is classified as a prescription-only (Rx-only) drug and is not federally listed as a controlled substance (such as a DEA Schedule I–V drug). Its status in other regions, such as the United Kingdom, is also prescription-only.


Q: Is there a specific food I should avoid while using Citox, according to official guidance?

A: No specific food is formally prohibited by regulatory documents. The medicine is officially approved to be administered with or without food, as studies have shown that absorption is not significantly affected by food intake.


Q: Where can I find the official research evidence summaries for Citox?

A: You can find official summaries of the clinical research and evidence used for regulatory approval on government drug agency websites. These documents, such as the U.S. Food and Drug Administration (FDA) Clinical Review, provide publicly available details on the studies.


Q: Does Citox interact with common over-the-counter pain relievers like ibuprofen?

A: Regulatory documents advise caution when this medicine is used alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or aspirin. Official information indicates this combination may increase the risk of abnormal bleeding or hemorrhage.


Q: What happens if I forget to take my Citox as directed?

A: Consumer patient information generally describes two options if a dose is missed: taking it as soon as it is remembered, or skipping it if it is closer to the next scheduled dose. Official guidance consistently states that patients should avoid taking double doses to compensate for a missed one.


Q: Are the reported weight changes caused by Citox permanent?

A: Weight changes (which can be either gain or loss) are documented in regulatory sources as a potential adverse reaction, particularly with long-term exposure. Official labeling describes the pattern of this effect but does not specifically use the term 'permanent' to classify the change.


Q: Have there been any studies on the long-term effects of using Citox for many years?

A: The established evidence base includes controlled maintenance studies that have lasted several months to one year or longer. Official regulatory labeling notes that the full safety profile and comprehensive risk data for use extending beyond four months in certain populations are not fully established.


Q: Are there specific population groups that were excluded from the main Citox studies?

A: Clinical trial data are generally reflective of the specific populations that were studied in those trials. Official information points out that data remains insufficient for certain groups, such as the very young (under age 7 for GAD), and caution is advised for specific subsets of older adults.


Q: Is it necessary to take Citox at the exact same time every day for it to be effective?

A: The official product information specifies that the medicine should be taken once daily, either in the morning or evening. While a long half-life means a single missed dose is less critical, consistent daily timing is recommended to help maintain steady blood levels for optimal effectiveness.


Q: Why do official documents sometimes mention the need for periodic blood tests when using Citox?

A: Official documents note the risk of Hyponatremia, which is a serious adverse reaction involving abnormally low sodium levels in the blood. Healthcare providers may recommend periodic blood tests to monitor sodium concentration, particularly for older adults who may be at a higher risk profile for this reaction.


Q: Does Citox interact with common anesthetic agents used in surgery?

A: Official information emphasizes that the prescribing healthcare provider should be fully informed of the patient’s medical history, including the use of this medicine, prior to any procedure involving anesthetic agents. This is due to the medicine's Serotonergic mechanism and potential effects on hemodynamic responses (blood circulation).


Q: How often should someone consult their doctor while using Citox, according to general guidelines?

A: Regulatory documents indicate that the long-term usefulness of the medicine for the individual patient requires periodic re-evaluation by the prescribing physician. Close monitoring by a healthcare professional is specifically recommended during the initial few months of therapy and following any dosage change.

How should Citox be stored and disposed of?

Storage and Disposal Requirements for Citox (Escitalopram)

Formulation Required Storage Condition Special Constraint
Tablets Store at Controlled Room Temperature (20 C to 25 C) or below 30 C Keep in original container, tightly closed
Oral Solution Store below 25 C Must be used within 8 weeks after opening

Citox must be stored out of the sight and reach of children to prevent accidental ingestion. The oral solution does not require refrigeration. For disposal, unused or expired medication must be handled in accordance with local requirements. If no specific local program is available, follow general guidelines, which typically involve mixing the medicine with an undesirable substance (such as used coffee grounds or dirt) before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citox found in:

A-Z Index: